Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex Incorporated (NYSE: TFX) has received 510(k) clearance from the U.S. FDA to extend the indications for use of the Arrow® EZ-IO® Intraosseous Vascular Access System. This device can now be utilized for up to 48 hours when traditional intravenous access is challenging. The expansion is particularly vital for patients requiring long-term access during emergencies.
According to Corporate Vice President Michelle Fox, this advancement aims to enhance patient care during times of resource constraints.
NeoTract, a subsidiary of Teleflex (NYSE: TFX), has recognized Dr. Erik Alexander from Arizona Urology Specialists as a UroLift® Center of Excellence for his expertise in treating Benign Prostatic Hyperplasia (BPH) with the UroLift System. This FDA-cleared, minimally invasive procedure offers an effective treatment for BPH symptoms without surgical side effects. Over 40 million men in the U.S. suffer from BPH, and the UroLift System has treated over 100,000 patients, providing durable symptom relief and improved quality of life.
Liam Kelly, Chairman, President and CEO of Teleflex (NYSE: TFX), will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 2:00 p.m. ET. A live audio webcast and slide presentation will be available on Teleflex's investor website. Teleflex is a global provider of medical technologies focused on improving health and quality of life through innovative solutions in various medical fields, including vascular access and anesthesia.
Teleflex Incorporated's CEO, Liam Kelly, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 12:40 p.m. (ET). A live webcast of his presentation will be accessible on the company's investor section of the website. Teleflex is a global medical technology provider focused on improving healthcare through innovative solutions across various medical fields such as vascular access, cardiology, and respiratory care.
Teleflex (NYSE: TFX) released its 2nd annual Global JOIN Impact Report, detailing progress made in 2019 on corporate social responsibility initiatives focusing on environmental sustainability and community engagement. The report highlights efforts in promoting pollination awareness under the theme ‘Planting with Purpose’. CEO Liam Kelly praised employee dedication to their mission of improving health and quality of life globally. The report is accessible via the company's website.
NeoTract, a subsidiary of Teleflex, has designated Dr. Robert Waguespack as a UroLift® Center of Excellence for his expertise in treating Benign Prostatic Hyperplasia (BPH). The UroLift System offers a minimally invasive solution for BPH, indicated by major urological associations and supported by clinical data showing rapid symptom relief. This procedure is gaining traction as an alternative to traditional medication and surgery, with over 100,000 men treated in the U.S. alone. The UroLift's FDA clearance and positive patient outcomes highlight its role in improving urological health for millions of men.
Teleflex (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share. This dividend will be paid on September 15, 2020 to shareholders recorded by the close of business on August 14, 2020. As a global provider of medical technologies, Teleflex focuses on innovations that enhance patient care. The company’s diverse portfolio includes solutions in areas like vascular access and anesthesia, reflecting its commitment to meeting clinical needs. For more details, visit teleflex.com.
Teleflex reported second quarter 2020 revenues of $567.0 million, a decline of 13.1% year-over-year, attributed largely to a $130 million revenue hit from COVID-19. GAAP diluted EPS fell 86.4% to $0.24, while adjusted diluted EPS decreased 27.4% to $1.93. The company announced a workforce reduction to improve cost structure and is not reinstating 2020 financial guidance due to ongoing pandemic uncertainties. Despite challenges, Teleflex holds over $550 million in cash and plans to continue generating long-term growth.
Teleflex announced that the UroLift System has successfully treated 200,000 patients suffering from benign prostatic hyperplasia (BPH), a condition affecting over 40 million men in the U.S. The minimally invasive device offers rapid symptom relief with quick recovery, allowing men to return to normal activities while preserving sexual function. The company's president noted the increasing physician adoption and positive real-world data supporting the UroLift's efficacy as a standard treatment for BPH.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
